NMRA
Neumora Therapeutics, Inc.Company Information
- Company Name
- Neumora Therapeutics, Inc.
- CIK
- CIK0001885522
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NMRA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- NMRA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-27
- Last sale
- 2026-08-21
- Shares purchased (TTM)
- 5,747,100
- Shares sold (TTM)
- 189,643
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 74,596,796
- Shares outstanding
- 185,163,000
- Ownership
- 40.29%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -18.13%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 117 | 147 | 183 | 129 | 125 | 127 | 142 | 276 | 151 | 183 | 374 | 412 | ||||||
| Restricted Cash Current | - | - | - | 0 | 0 | 1 | 1 | 1 | - | - | - | - | ||||||
| Marketable Securities Current | - | - | - | 42 | 93 | 122 | 165 | 66 | 221 | 240 | 80 | 97 | ||||||
| Prepaid Expense And Other Assets Current | 8 | 6 | 8 | 6 | 5 | 4 | 5 | 6 | 27 | 20 | 24 | 16 | ||||||
| Assets Current | 125 | 153 | 191 | 177 | 223 | 255 | 314 | 349 | 398 | 443 | 478 | 526 | ||||||
| Marketable Securities Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 10 | 10 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 3 | 4 | 5 | 6 | ||||||
| Restricted Cash Noncurrent | - | - | - | - | - | - | 0 | - | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Assets | 125 | 154 | 191 | 178 | 224 | 257 | 317 | 353 | 404 | 450 | 496 | 545 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 3 | 1 | 1 | 1 | 3 | 6 | 1 | 1 | 0 | 2 | ||||||
| Accrued Liabilities Current | 23 | 25 | 29 | 25 | 20 | 26 | 25 | 23 | 18 | 19 | 21 | 23 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 4 | 3 | 3 | 3 | ||||||
| Liabilities Current | 28 | 30 | 32 | 26 | 21 | 28 | 30 | 32 | 23 | 25 | 25 | 29 | ||||||
| Long Term Debt Noncurrent | 53 | 53 | 55 | 20 | 19 | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | - | - | - | - | 1 | 2 | 3 | ||||||
| Liabilities | 81 | 83 | 87 | 46 | 41 | 28 | 30 | 32 | 23 | 26 | 27 | 32 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 1,325 | 1,308 | 1,288 | 1,257 | 1,251 | 1,244 | 1,234 | 1,209 | 1,197 | 1,182 | 1,173 | 1,108 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,281 | -1,238 | -1,184 | -1,125 | -1,068 | -1,015 | -947 | -888 | -816 | -757 | -703 | -595 | ||||||
| Stockholders Equity | 45 | 71 | 104 | 132 | 183 | 228 | 287 | 321 | 381 | 425 | 469 | 513 | ||||||
| Liabilities And Stockholders Equity | 125 | 154 | 191 | 178 | 224 | 257 | 317 | 353 | 404 | 450 | 496 | 545 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | - | - | 50 | - | - | - | 50 | - | - | - | 50 | - | ||||||
| Preferred Stock Shares Issued | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | 50 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Preferred Stock Shares Outstanding | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | 700 | - | - | - | 700 | - | - | - | 700 | - | ||||||
| Common Stock Shares Issued | - | - | 174 | - | - | - | 162 | - | - | - | 159 | - | ||||||
| Shares Outstanding | - | - | 174 | - | - | - | 162 | - | - | - | 159 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialNeumora Therapeutics, Inc. (NMRA) — SEC Financial Statements & Analysis
Neumora Therapeutics, Inc. (NMRA) is a biological products, (no diagnostic substances) company, incorporated in DE. Neumora Therapeutics, Inc. trades on Nasdaq as: NMRA. Neumora Therapeutics, Inc. (NMRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Neumora Therapeutics, Inc. carries a market cap of $314.78M, a P/E ratio of -1.48x, a P/B ratio of 7.07x, an enterprise value of $250.86M, and an EV/EBITDA multiple of -1.19x. On profitability, it posts a Return on Equity (ROE) of -187.11%, a Return on Assets (ROA) of -121.89%, and a Return on Invested Capital (ROIC) of -725.78%. Per share, it reports EPS of $-1.15, diluted EPS of $-1.15, free cash flow per share of $-0.98, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -15.61% year-over-year and EPS growth of -26.31% year-over-year. On the balance sheet, it maintains a current ratio of 4.50x, a quick ratio of 4.21x, working capital of $97.10M, a debt-to-equity ratio of 1.81x, a debt ratio of 0.64, an interest coverage ratio of -32.71x, free cash flow of $-180.54M (TTM), and net debt of $-63.92M. Figures sourced from SEC EDGAR.
- Market Cap
- $314.78M
- P/E TTM
- -1.48x
- EPS TTM
- $-1.15
- P/B TTM
- 7.07x
- ROE TTM
- -187.11%
- ROA TTM
- -121.89%
- Debt To Equity
- 1.81x
- Free Cash Flow TTM
- $-180.54M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Neumora Therapeutics, Inc. in?
Neumora Therapeutics, Inc. (NMRA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does NMRA trade on?
Neumora Therapeutics, Inc. (NMRA) trades on the Nasdaq.
Where is Neumora Therapeutics, Inc. incorporated?
Neumora Therapeutics, Inc. is incorporated in DE.
When was Neumora Therapeutics, Inc. (NMRA)'s most recent SEC filing?
Neumora Therapeutics, Inc. (NMRA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is NMRA's market cap?
Neumora Therapeutics, Inc. (NMRA) has a market capitalization of $314.78M as of 2026-06-30.
What is NMRA's EPS (earnings per share)?
Neumora Therapeutics, Inc. (NMRA)'s trailing twelve month EPS is $-1.15 as of 2026-06-30.
What is NMRA's ROE (return on equity)?
Neumora Therapeutics, Inc. (NMRA)'s trailing twelve month Return on Equity (ROE) is -187.11% as of 2026-06-30.
What is NMRA's ROA (return on assets)?
Neumora Therapeutics, Inc. (NMRA)'s trailing twelve month Return on Assets (ROA) is -121.89% as of 2026-06-30.
What is NMRA's ROIC (return on invested capital)?
Neumora Therapeutics, Inc. (NMRA)'s trailing twelve month Return on Invested Capital (ROIC) is -725.78% as of 2025-09-30.
What is NMRA's EV/EBITDA?
Neumora Therapeutics, Inc. (NMRA)'s trailing twelve month EV/EBITDA is -1.19x as of 2026-06-30.